GcMAF Therapy Case Reports
Below are short case reports of our clinical experience using GcMAF immunotherapy in our clinic at Saisei Mirai. Most patients are on a variety of both conventional and complementary therapies and frequently they come to the clinic after conventional methods have failed. Since our therapies are non-toxic, they may be used successfully at any stage to improve quality of life (QOL), prolong life and cure the disease.
Oral Colostrum MAF for Infection in a 74-Year Old Terminal Pancreatic Cancer Patient
- 74 -year old female with pancreatic cancer
- Multiple liver metastasis
- Rheumatoid arthritis
- The patient was admitted to hospice for terminal care.
- 4-Oct-2014 – Continuing high fever.
- 8-Oct-2014 – Loss of consciousness.
- 10-Oct-2014 – Admitted to another hospital for emergency tests and treatment. No evidence of pneumonia was found.
- 14-Oct-2014 – The patient returned to the hospice and received intravenous hyperalimentation (IVH) feeding.
- The patient remained in deep coma, high fever continued, antibiotics showed no effect.
- Antibiotics caused renal function disorder.
- 18-Oct-2014 – Diagnosed to have only hours to several days to live. Family gathered to take leave of the patient.
- 18-Oct-2014 – The patient’s son gave oral colostrum MAF powder by sublingual administration with small amount of water twice a day.
- The next day, the patient showed a reduction in fever.
- After 3 days, the fever had almost disappeared.
- 29 Oct 2014 After 3 weeks in a coma and 11 days after starting on Oral Colostrum MAF, the patient opened her eyes and was able to follow movements with her eyes.
- 4 Nov 2014 The patient started to talk and wanted to eat. She was surprised that it was already November.
- Eating rehabilitation was started.
- The doctor in the hospice said the result was a miracle. It was his first case out of 2000 patients who had died in the same situation.
- The physician called Oral Colostrum MAF an amazing medicine.
This case report was first presented by Dr Toshio Inui on 13 December 2014 at the 18th Annual Meeting of the Society of Biotherapeutic Approaches, Takamatsu, Japan.
45-year old male with Multiple Sclerosis (MS) – Terminal Stage Progressive
- 24-year old with multiple sclerosis (MS)
- Terminal stage progressive
- Wheelchair-bound for 4 years
- Severe muscle pain and twitching
- Told he is in terminal stage with no improvement in sight
- 1991 First developed symptoms of multiple sclerosis (MS)
- 2004 Scans showing extensive lesions in brain and spinal cord indicating secondary progressive MS
- 2012 Neurologist: The patient has now developed secondary progressive MS. There is no known effective treatment for this condition, the patient is confined to a wheelchair and will not be able to walk again.
Symptoms: Insomnia, bladder infections needing to void 10 times per night, optic neuritis (inflammation of the optic nerve), severe muscle pain and twitching, confusion, weakness, wheelchair bound, unable to walk or stand. Multitude of bacterial infections.
- 17 Sep 2014 – Started Second Generation GcMAF therapy
- 0.5 ml High-Dose GcMAF (1500 ng/0.5 ml) twice weekly
Initial Response After 3 Weeks of Treatment with Second-Generation Gcmaf
Responded very well from the start to GcMAF. Slept through the night to 7 AM without emptying his bladder. Has gone off all medications for pain and bladder control and is off antibiotics. Has more energy and is able to drive an adapted car. Is returning to work every day. However, still doesn’t walk and still subject to some confusion.
Response after 6 weeks of treatment with second-generation GcMAF
Has full bladder control and is off medication for bladder infections, likewise patches to assist bladder to function. Brain fog is much better. Is animated and content.
- 31 Oct 2014 – The patient is able to walk with assistance for the first time after 4 years being wheelchair bound. The next day, is able to walk unassisted and walk up and down stairs.
The patient is continuing treatment with second-generation GcMAF.
61-Year Old Male Hepatitis C Virus (HCV) Patient from Israel with Sarcoma Treated by Dr Eyal Attias
Dr Eyal Attias at a clinic in Israel; Dr Toshio Inui and Dr Eyal meet in Japan (30 Jan 2014).
- High-dose GcMAF
- Ozone therapy
Patient information and summary of results:
- 61 -year old male patient from Israel with severe liver disease due to Hepatitis C virus (HCV) infection.
- Amputation high above left knee plus left lobectomy due to malignant sarcoma with lung metastasis.
- The patient also suffers from Chronic Obstructive Pulmonary Disease (COPD) – a lung disease, congestive heart failure (CHF), hypertension and from Type 2 diabetes mellitus (HbA1c <7).
- Due to very severe condition, the patient was unable to take conventional HCV therapy and instead opted for High-Dose GcMAF and ozone therapy.
- Metastatic tumors shrank and his hepatitis C viral load in the blood decreased from extremely high level of 1 billion/ml to 18 million/ml.
- The positive result was considered to be due to the combination of High-Dose GcMAF and ozone therapy.
- The patient was refused financial support for medical treatment by the Israeli Ministry of Defense, Veterans Handicap Rehabilitation Organization and subsequently appealed to the Supreme Court of Israel.
- A senior judge asked Prof Ran Oren at the Hadassah University Hospital in Jerusalem to undertake a professional medical review of the case.
Prof Ran Oren from the Hadassah University Hospital in Jerusalem
- Prof Oren consulted with colleagues around the world. He concluded that in all his career of more than 30 years he never saw a patient with such severe case of hepatitis C who survived like this patient.
- After confirming the patient’s miraculous recovery, the Supreme Court ordered that GcMAF and ozone therapy treatment be continued until full recovery and financial support from the Israeli Ministry of Defense.
Female Aged 64 with Stage 4 Lung Cancer and Adenocarcinoma
Integrative Therapies: Iressa targeted therapy, 1500 ng High-Dose GcMAF 2 times weekly IM injection for 6 months (48 times in total), regional hyperthermia, 8 times (Thermotron RF8), 4.5 mg Low-Dose Naltrexone (LDN) daily.
The primary doctor was surprised because the result expected from the targeted therapy was merely disease stability (rather than a cure) because of the advanced stage. However, the tumor completely disappeared with only some scar tissue remaining in the lungs.
The patient achieved a complete recovery by August 2013.
- In remission: The patient is continuing 1500 ng High-Dose GcMAF 1 time/week (48 doses) for about a year to reduce the risk of recurrence.
Male Aged 70+ with Glioblastoma Multiforme Brain Cancer
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Treatment can involve chemotherapy, radiation and surgery. Median survival with standard-of-care radiation and chemotherapy with temozolomide is 15 months. Median survival without treatment is 4.5 months. Less than 15% of patients survive two years.
A patient, in his 70s, used tumor-derived cancer vaccine and then continued with cMAF long-term. The patient is still alive and well after two years.
60 -year old male with prostate cancer, Gleason score 8
- 60 -year old male, with prostate cancer
- Gleason score 8 (range 2 to 10)
- Initial diagnosis Feb 2011
- Feb 2011 radical prostatectomy, lymph node (–)
- No hormonal therapy
- PSA after surgery was increasing
- Oct 2011 to Dec 2011 radiation, 60 Gy dose
- May 2012 to Apr 2013 autologous serum GcMAF 72 times, IM (1500 ng/0.5 ml), high-dose IV vitamin C 60 g, 72 times
- Regional Hyperthermia, 21 times (Thermotron RF8)
- Feb 2013 MRI shows no metastatic tumors
- 2014 Normal PSA 0.058 ng/ml, no recurrence
60 -year old male with prostate cancer, Gleason score 8 diagnosed in February 2011. He received radical prostatectomy without hormone therapy but after surgery, the PSA increased again. He received radiation therapy, 60 Gray to the pelvic region. In May 2012, he presented himself at Saisei Mirai. He received 72 times 0.5 ml high-dose GcMAF (1500 ng/0.5 ml), high-dose IV vitamin C 60g and 21 times regional hyperthermia using Thermotron RF8.
In February 2013, MRI showed no metastatic tumors. The latest PSA level in 2014 was 0.058 ng/ml with no recurrence.
This case report was first presented by Dr Toshio Inui on 29 Jun 2014 at the 9th International Congress for Medical Laser Applications, Germany. The full presentation can be found here (PDF).
62-Year Old Female with Uterine Cancer and Lymph Node Metastasis, Stage 4B
The patient was diagnosed with stage 4B after initial surgery in February 2011. Pathological diagnosis was serous adenocarcinoma.
Prior treatment was two times chemotherapy in March 2011 using Carboplatin and Paclitaxel. After two applications of chemotherapy, the Pet CT showed recurrence in the left iliac artery and lymph nodes and tumor markers were elevated. The patient then had a second surgery of lymph nodes metastasis in the pelvis and left inguinal region and in addition prophylactic surgery.
In July 2011, the patient had more chemotherapy with CDDP and radiation therapy but new recurrence was found in the lymph node near the abdominal aorta which was followed by a fourth operation in November 2011, with simultaneous radiation therapy to the area near the abdominal aorta.
The patient presented himself at the Saisei Mirai Clinic in Osaka in December 2011 after extensive prior treatment. Chemotherapy had been discontinued due to the poor condition of the patient from side effects.
Immunotherapy was started at our clinic from December 2011, initially with Regional Hyperthermia, 400 mg/day Maitake MD-fraction and Low-Dose Naltrexone (LDN). Maitake MD-fraction and LDN were continued long-term. Coley Vaccine therapy (Coley Toxin’s) was started in January 2012 and High-Dose GcMAF (1500 ng, 0.5 ml) as of February 2012.
Intravenous Coley Vaccine was administered a total 110 times, starting with 5 times in the 1st week, 2 times in the second- week, followed by 5 times in the 3rd week etc., eventually finishing with 1 time per week. High-Dose GcMAF (a total of 48 times) was administered once a week over a period of one year.
By 2013 patient achieved complete remission. No tumor was visible on the CT scan and the tumor marker was at the bottom end of the normal range.
71-Year Old Male with Malignant Thymoma (Cancer of The Thymus Gland) and Lung Metastases
High-Dose GcMAF (1500 ng, 0.5 ml) was administered once a week (total 48 times) together with weekly high-dose intravenous Vitamin C (total 56 times). After one year, the patient still has good quality of life (QOL) with stable disease and no change in tumour size. The patient discontinued GcMAF because he felt the treatment had been successful, however, 6 months later the CT showed renwewed tumor growth. After this result. the patient decided to continue treatment with GcMAF.
Currently, the patient’s condition is stable with a good QOL.
74-Year Old Male with Prostate Cancer and Multiple Bone Metastases
High-Dose GcMAF (1500 ng, 0.5 ml) was administered once a week (total 24 times) together with weekly high-dose intravenous vitamin C (total 39 times). Local Hyperthermia (Thermotron RF8) was added once a week (total 19 times). The patient had a complete recovery. The primary tumor and multiple bone metastases all disappeared as seen in the bone scintigram (bone scan/bone scintigraphy) and MRI.
72-year old female with colon cancer and metastatic liver tumor, ovarian tumor and peritonitis carcinomatosa
First, the patient had surgery to remove the tumor in the colon and the ovary was also removed. She then took High-Dose GcMAF (1500 ng, 0.5 ml) treatment once a week (for a total of 48 times) and high-dose intravenous vitamin C once or twice a week (for a total of 66 times). During this period, she took targeted radiation therapy (Novalis Tx Radiosurgery) to the liver tumor at a dose of 55Gy. After one year of treatment, the PET CT scan showed no recurrence of the tumor. The patient is still in complete remission.
76-Year Old Female with Pulmonary Infections Due to Nontuberculous Mycobacteria Of The Lung
The 3 Feb 2011 chest X-ray before GcMAF therapy showed active pulmonary infiltrations. The 22 Nov 2012 chest X-ray after GcMAF therapy showed only scar tissue without active pulmonary infiltrations after treatment.
The patient took conventional therapy with all available tuberculosis antibiotics for 10 years with good effect, initially. After 10 years of treatment, tolerance to the drugs increased and the therapy lost its effectiveness. She thereupon decided to start high-dose intravenous vitamin C (25 g) once a week (a total of 239 times) over a 4-year period and took High-Dose GcMAF (1500 ng, 0.5 ml) once a week (a total of 41 times) for about one year near the end of the 4-year period. After 4 years of treatment, a chest CT scan showed only scar tissue without active pulmonary infiltrations.
Female with lung cancer – Low-dose (palliative) radiation plus GcMAF
One month after GcMAF therapy plus one-time low-dose palliative radiation for lung cancer.
The image at right shows that the tumor shrank by half. Radiologists treating the patient were surprised to see such a strong cancer killing effect which is not expected with small doses of radiation.
The advanced-stage lung cancer patient had low-dose palliative radiation to their right lung (left side on the scan) to treat cough and breathing difficulty caused by cancer. This radiation therapy was not designed to have a significant effect on the cancer but was applied simply to treat the symptoms. After one-time palliative radiation treatment and High-Dose GcMAF (1500 ng, 0.5 ml) therapy, the patient’s right-side lung (at left in the image) shrank by half and the tumor marker also decreased by half from CEA 890 ng/ml to 426 ng/ml two months later.
Radiologists treating the patient were amazed at the good effect which was not usual or expected with this kind of low-dose radiation treatment. Symptoms greatly improved with a significant decrease in cough and improved breathing and the patient remained active with good quality of life. We believe that the use of multimodality integrative therapy of GcMAF plus a low dose of radiation was enough to be effective, avoiding serious side effects of regular high-dose radiation. What is more surprising is that this occurred at the very advanced stage having undergone all available therapies (such as chemotherapy) just when treatments became less effective as the cancer became resistant and difficult to treat. When using GcMAF therapy, better results are seen with local treatments such as radiation (avoiding the bone marrow) over systemic conventional chemotherapies which harm the immune system.